Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response- and Biology-Based Risk Factor-Guided Therapy in Non-High-Risk Neuroblastoma
NCT02176967Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Aug 2014
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 6
01
Overview
Phase 3, open-label trial of carboplatin, etoposide, cyclophosphamide and pegylated liposomal doxorubicin in neuroblastoma and ganglioneuroblastoma (GNB) (3 arms), sponsored by Children's Oncology Group. Primary endpoint: Overall survival at 3 years. Started Aug 2014; status: active, not recruiting.
02
Drugs
carboplatinetoposidecyclophosphamidepegylated liposomal doxorubicin
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT02176967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176967.